Novel p53 mutation in a malignant tumor secreting vasoactive intestinal peptide

J. Lin Henry, Samuel W. French, Dennis Reichenbach, Yu-Jui Yvonne Wan, J. Edward Passaro, Mark P. Sawicki

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Objective. - To assess involvement of p53 mutations in development of pancreatic endocrine tumors. Design. - Survey of sporadic pancreatic endocrine tumors. Setting. - Hospital referral centers, mainly in the Los Angeles, Calif, area. Patients. - We obtained fresh surgical specimens from 25 patients (convenience sample) with no family history of endocrine tumors and no evidence of multiple endocrine neoplasia 1 or yon Hippel-Lindau disease. Preoperative tests included serum peptide analysis. Main Outcome Measures. - DNA was prepared from tumor specimens. We screened exons 5 through 8 of the p53 gene using single-strand conformation polymorphism analysis, followed by DNA sequencing when a variant was detected. Results. - A three-base deletion mutation (codon 239) was found in one malignant tumor secreting vasoactive intestinal peptide. Conclusions. - p53 appears to have a limited role in development of pancreatic endocrine tumors. However, evidence from one of our patients suggests it may be involved in tumor progression in uncommon cases.

Original languageEnglish (US)
Pages (from-to)125-128
Number of pages4
JournalArchives of Pathology and Laboratory Medicine
Volume121
Issue number2
StatePublished - 1997
Externally publishedYes

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Fingerprint Dive into the research topics of 'Novel p53 mutation in a malignant tumor secreting vasoactive intestinal peptide'. Together they form a unique fingerprint.

Cite this